REPOST (Now with less picking on Craig!) I asked

New Post Public Reply Private Reply Replies (0) Message Board
Respert24
583
REPOST

(Now with less picking on Craig!)

I asked ChatGPT if AI will be able to replace human trials for investigational drug approvals in the future. Here is what she* said.

*Remember when Dishwalla sung about god being a woman in a way that you just knew meant they were trying to be far deeper than they were? Yeah, uh, me neither.

ChatGPT Says:


As of my last knowledge update in September 2021, AI has made significant strides in drug discovery and development, but completely replacing human trials for investigational drug approvals is a complex and multifaceted challenge. Here are some factors to consider:

1. Complexity of Human Biology: Human bodies are incredibly complex, and the interactions between drugs and our physiology are intricate and varied. While AI can simulate some of these interactions in silico (in a computer), it is challenging to capture the full complexity of human biology in a virtual environment.

2. Safety and Efficacy: One of the primary goals of clinical trials is to determine the safety and efficacy of a drug in humans. This involves not only looking at how a drug interacts with the body, but also understanding its impact on different patient populations, potential side effects, and long-term effects. AI can assist in the early stages of drug development, but understanding these aspects requires real-world trials.

3. Unforeseen Interactions: New drugs can have unforeseen interactions with existing medications, or with specific genetic or environmental factors. These interactions are difficult to predict using AI alone.

4. Regulatory Approval and Ethical Considerations: Regulatory bodies, such as the FDA in the United States, have established rigorous standards for drug approval. These standards are based on a wealth of historical evidence and prioritize patient safety. Moving from human trials to a solely AI-based system would require a major shift in global regulatory frameworks.

5. Patient Variability: Humans are highly variable. Factors like age, genetics, lifestyle, and environment can significantly impact how individuals respond to drugs. Clinical trials are designed to capture this variability.

6. Real-World Data Challenges: While AI can analyze large amounts of data, much of it comes from controlled clinical trial environments. Real-world data is messier and often harder to interpret. Incorporating this kind of data into a solely AI-driven approval process would be a significant challenge.

7. Ethical Considerations and Public Trust: There are ethical considerations surrounding the use of AI in healthcare. Patients and the public need to trust that new drugs have been thoroughly tested and are safe.

While AI is revolutionizing drug discovery by expediting the initial stages of identifying potential drug candidates, predicting their behavior, and even suggesting combinations, it is unlikely, at least in the foreseeable future, to fully replace human trials for investigational drug approvals. The gold standard of clinical trials serves a vital role in ensuring patient safety and drug efficacy. The future likely involves a synergistic relationship between AI and traditional clinical trials, with AI aiding in the design and optimization of trials.



Now that I've put that subject to bed, I also asked ChatGPT whether or not it thinks Cytodyn will have any catalysts hit this month.

It claimed it hasn't been updated in a couple years and can't predict the future, which is bullshit. I can't believe I'm not allowed to just hammer the keys on my laptop into questions that get immediately and accurately answered. What the fuck am I getting for the $1,000 I spent on this Lenovo laptop then?

Sticky keys?

That's it?

Bummer.

Oh wait, I do remember that there's one other thing I get with this laptop. Every month it will decide that it no longer has fingerprint recognition. Then after some updates it'll be like, Hey buddy, wanna use your fingerprint? I'm all ready for it. Which finger are you gonna use? Pointer? Nice call. Strong choice, the pointer. Now nestle that thing up on this tiny square and let's open your laptop. Mmm, I'm sure McAfee missed you while you were gone. Wanna scan some files together? Watch some black boxes needlessly flash on the screen for a nanosecond and never come back to explain why the hell you needed to see it? Maybe pop up an insufferable amount of reminders about what McAfee could do for you if you'd just let it? Why aren't you letting McAfee help you? McAfee can teach you many things, but McAfee won't beg. Come to Omaha with McAfee and let McAfee introduce you to some new experiences. Hey, where are you going? Reddit? Oh come on, it's a cesspool over there and they no longer let you give those little widget emoji things, I heard. Hey! Remember when you could buzz people on yahoo messenger? That was fun. A simple pleasure. Like making the dial up internet sounds back when you couldn't just connect in a millisecond, you had to wait for your computer to scream at you in various pitches for like ten seconds first. And you needed a CD at one point! Awww, CD's were the shit. I miss em. Even a Dishwalla album seemed cool when it was packaged in that unnecessarily sized rectangle package that only had the disc in the top half with the bottom half existing for no apparent reason.

I guess what I'm trying to say is buy low and sell high. Or, buy low then high, then chase it down and keep buying, and then say you're not going to buy any more but then buy more multiple times because it's so goddamn cheap right now. Then sit back and wait for the dominoes to start falling. But also buy more between now and then.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's in Hot Water? Fiduciary Duty Concerns Loom

Updated Category News Views 55

Shareholder Rights On The Line You ever get that itch, the one that whispers something's off with a company? Well, that itch might be turning into a rash at Domino's Pizza, Inc. (NASDAQ: DPZ). Shareholders are being nudged to jump into the fray as Halper Sadeh LLC investigates potential wrongdoings by some of the pizza titan's bigwigs. The spotlight is on whether these...

Continue Reading
Saga Metals Advances Radar Project with HQ Drill Success

Updated Category News Views 117

Digging Deep at Trapper North: Saga's Strategic Drill Move There's nothing like the thrill of discovery, especially in the rough-and-tumble world of mining exploration. Saga Metals Corp., anchored deep in the critical minerals scene, has wrapped up an HQ-diameter drill program at its Radar Project, smack dab near Cartwright, Labrador. You hear 1,010 meters and maybe...

Continue Reading
Crude Insight: Refining Margins Expand, LNG Orders Rise

Updated Category News Views 166

Refining Margins Stretch While LNG Orders Surge Well, folks, oil markets have sure been a rollercoaster lately. WTI futures danced all over the place, closing near $96 a barrel after brushing against both $93 and $99 earlier this week. Brent wasn't left out of the tango, setting at $103.60. Everyone's holding their breath each time these numbers come through. Energy...

Continue Reading
Guaranteed Income Policies Gain Traction Across States

Updated Category News Views 62

Big Wins for Guaranteed Income Programs Boy, isn't it fascinating watching the political gears turn to embrace concepts like guaranteed income? This wave of enthusiasm isn't just words and ideas; it's now showing up in election results and ballot measures in multiple states. From California to Pennsylvania, voters appear to dig the idea of direct cash assistance to those...

Continue Reading
Compass Datacenters Welcomes Texas Governor-Elect Hinojosa

Updated Category News Views 49

The Data Game in Texas Just Got Interesting Today's headlines aren't short of drama, but here's one that's got my attention. Compass Datacenters is casting a hopeful eye toward the incoming Texas Governor, Hinojosa. It's a name to remember—not just for politicos but for anyone with a thumb in the data pie. As these folks see it, Hinojosa's election isn't just about...

Continue Reading
REELZ Gears Up for 75th Miss Universe Pageant

Updated Category News Views 99

A Global Celebration Comes to REELZ Let's dive straight into the glitz and spectacle—REELZ isn't just broadcasting some regular program. They're handing us the 75th Miss Universe pageant on a silver (or maybe gold, in this case) platter. Come November 24, at 8 PM ET, expect your screen to light up with beauty, culture, and a hefty dose of competition, as it unfolds live...

Continue Reading
New Story Appoints Drudge, Celebrates Workplace Recognition

Updated Category News Views 103

A Dual Milestone: Leadership and Recognition In an industry chock-full of buzzwords, New Story’s latest moves cut through the noise. They've just announced Adam Drudge as their new Chief People Officer, and wouldn't you know it, they've snagged their third straight Most Loved Workplace® recognition for 2026. When a special ed company starts making waves like this,...

Continue Reading
Bluerock Fund Declares November Distribution With Strategic Growth

Updated Category News Views 42

Navigating Bluerock's Latest Moves Bluerock Private Real Estate Fund (BPRE) is up to something intriguing, dishing out a $0.1371 cash distribution per share for November 2026. If you're a shareholder of record by November 18, you're lined up for a payday on November 30. This decision reflects a solid 7.5% distribution rate on NAV, with an eye-popping annualized market...

Continue Reading
Class Action Targets Extremist Groups, Interference

Updated Category News Views 57

Legal Spar on the Horizon: Class Action Commences The legal world now sees a fresh duel as Impresa Legal Group rolls up its sleeves and files a class action lawsuit against certain extremist groups and foreign-funded entities. At the heart of this legal action are accusations that these outfits have orchestrated a campaign to intimidate data center workers while meddling...

Continue Reading
Virginia Home Projects: Navigating 2026 Material Costs

Updated Category News Views 94

Penny-Pinching with Pricey Planks: Lumber's Wild Ride Every single time you pick up a hammer, it's like gambling on the money pit that is lumber pricing. These costs are so all over the board in 2026, they make whipping your checkbook out feel like a game of roulette. Folks over in Culpeper and the greater Virginia space are no strangers to this chaotic dance. Travis...

Continue Reading

Top 5 Most Recently Viewed Articles

Limoneira Company's Q3 Growth: A New Era of Success

Updated Category News Views 125

Limoneira Company Delivers Strong Q3 2024 Results Limoneira Company (NASDAQ: LMNR), a diversified grower with deep roots in citrus and a meaningful real estate platform, turned in a strong third quarter of fiscal 2024. Net revenue rose 21% to $63.3 million, driven mainly by brisk sales of fresh lemons and avocados. Adjusted EBITDA climbed to $13.8 million from $2.8...

Continue Reading
FORVIA Adjusts FY 2024 Guidance Amid Market Uncertainties

Updated Category News Views 198

FORVIA updated its full-year 2024 guidance, revealing a dim outlook for the automotive tech supplier as it faced market turbulence. The company slashed its sales expectations to a range of €26.8 billion to €27.2 billion, down from previous estimates of between €27.5 billion and €28.5 billion. This drastic reduction indicates a clear struggle against shifting...

Continue Reading
Circle's Q4 Earnings Preview: What's Cooking in the Market?

Updated Category News Views 188

Circle Poised To Repeat Stellar Results? Yes, folks, it's that time again—earnings season is knocking on the door and Circle's about to strut its stuff. Analysts are expecting earnings per share of $0.16. That’s a staggering 75% drop from the previous quarter’s highs. Makes you wonder if they’ve been hit with a shareholder sucker punch, right? But hold onto your...

Continue Reading
Nordic Fibreboard AS Announces Exciting Share Offering

Updated Category News Views 190

Nordic Fibreboard AS Announces Additional Public Share Offering Nordic Fibreboard AS, a prominent player in the building materials sector, is thrilled to announce the additional public offering of its shares. This unique opportunity is exclusively available to existing shareholders, who are entitled to take part in the offering through pre-emptive subscription rights....

Continue Reading
FIBRA Prologis Reports Strong Performance in 2024 Earnings

Updated Category News Views 206

FIBRA Prologis Reports Impressive 2024 Earnings Results In a recent announcement, FIBRA Prologis (BMV:FIBRAPL 14), a top operator of Class-A industrial real estate, showcased its remarkable performance for 2024. With a strategic focus on growth, the company reported significant achievements in net effective rents, occupancy rates, and customer retention. Highlights of the...

Continue Reading